Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Blood (2018) 132 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2018-99-112847

Published: 2018

Journal Articles

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Youn H Kim, MD, Sean Whittaker, MB, ChB, FRCP, MD, Steven M Horwitz, MD, Madeleine Duvic, MD, Reinhard Dummer, MD, Julia J Scarisbrick, MBChB FRCP MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD PhD, Pascal Wolter, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Erin Zagadailov, PharmD, MS, William L Trepicchio, PhD, Yi Liu, PhD, Meredith Little, MPH, H Miles Prince, MD

Blood (2016) 128 (22): 182.

https://doi.org/10.1182/blood.V128.22.182.182

Published: 2016

Journal Articles

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Blood (2012) 120 (23): 4513–4516.

https://doi.org/10.1182/blood-2012-05-426924

Published: 2012

Includes: Supplemental data

Journal Articles

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

George Mulligan, PhD, David I Lichter, MS, Alessandra Di Bacco, PhD, Stephen J Blakemore, PhD, Allison Berger, PhD, Erik Koenig, Hugues Bernard, William L. Trepicchio, PhD, Bin Li, PhD, Sagar Lonial, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Pieter Sonneveld, MD, PhD, Jesús F San Miguel, MD PhD, Dixie-Lee Esseltine, MD, FRCPC, Matthew Schu, MS

Blood (2011) 118 (21): 1377.

https://doi.org/10.1182/blood.V118.21.1377.1377

Published: 2011

Journal Articles

High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib.

Hadi Danaee, Barb Bryant, Steve Roels, Dave Lichter, Eric Koening, William L. Trepicchio, Anthony Boral, Paul Richardson, Yan Meng, Peter Leif Bergsagel, Pieter Sonneveld, Annemiek Broyl, Constantine Mitsiades, Wee-Joo Chng, Kenneth Anderson, George Mulligan

Blood (2007) 110 (11): 4763.

https://doi.org/10.1182/blood.V110.11.4763.4763

Published: 2007

Journal Articles

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

George Mulligan, Constantine Mitsiades, Barb Bryant, Fenghuang Zhan, Wee J. Chng, Steven Roels, Erik Koenig, Andrew Fergus, Yongsheng Huang, Paul Richardson, William L. Trepicchio, Annemiek Broyl, Pieter Sonneveld, John D. Shaughnessy, Jr, P. Leif Bergsagel, David Schenkein, Dixie-Lee Esseltine, Anthony Boral, Kenneth C. Anderson

Blood (2006) 109 (8): 3177–3188.

https://doi.org/10.1182/blood-2006-09-044974

Published: 2006

Includes: Supplemental data

NARROW

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib.

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

Email alerts

ASH Publications

American Society of Hematology

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib.

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only